A CQUISITION OF NEUROMUSCUlar dysfunction after admission to the intensive care unit (ICU) has been described during the last decade. Although this condition was first reported in a patient with severe asthma who required high doses of corticosteroids and neuromuscular blocking agents, 1 neuromuscular dysfunction acquired in the ICU has also been frequently reported in patients with sepsis or multiple organ dysfunction or both. 2 Peripheral nerve conduction abnormalities have been identified by electrophysiologic examinations, leading to the label critical illness polyneuropathy. 3 The incidence rate and risk factors for ICU-acquired neuromuscular disorders have been reported in prospective observational studies based on electrophysiologic or histologic examination. 4, 5 In these studies, electrophysiologic abnormalities ranged from 47% to 90% of the patients, 2,6-8 and histologic abnormalities ranged from 71% to 96%. 7, 9 The sample sizes of these cohorts ranged from 20 to 70 patients. However, despite the potential impact of ICU-Results Among the 95 patients who achieved satisfactory awakening, the incidence of ICUAP was 25.3% (95% confidence interval [CI], 16.9%-35.2%). All ICUAP patients had a sensorimotor axonopathy, and all patients who underwent a muscle biopsy had specific muscle involvement not related to nerve involvement. The median duration of ICUAP after day 1 was 21 days. Mean (SD) duration of mechanical ventilation after day 1 was significantly longer in patients with ICUAP compared with those without (18.2 [36.3] Conclusions Identified using simple bedside clinical criteria, ICUAP was frequent during recovery from critical illness and was associated with a prolonged duration of mechanical ventilation. Our findings suggest an important role of corticosteroids in the development of ICUAP. JAMA. 2002; 288:2859 -2867 www.jama.com acquired paresis (ICUAP) on important outcomes, such as the duration of weaning from mechanical ventilation and the duration and cost of ICU stay, the incidence and severity of clinical abnormalities remain poorly understood. To our knowledge, there are no published data on the incidence and risk factors of severe clinical weakness in the general ICU population and in particular after recovery from acute illness and improvement in consciousness, when identification of paresis is particularly relevant for the clinician. The difficulty in evaluating muscle strength in ICU patients may contribute to the lack of information. The unavailability of electrophysiological examination in many ICUs and the reluctance to obtain histologic samples in practice further support the need for a bedside approach to this condition.
The objectives of this prospective, multicenter study were to assess the clinical incidence, features, risk factors, and outcome of ICUAP identified by bedside clinical examination in ICU patients during recovery from severe illness (primary objective) and to determine the electrophysiologic and histologic patterns of ICUAP (secondary objective).
METHODS

Eligibility for Clinical Neuromuscular Evaluation
The study began in March 1999. Patients were enrolled in 5 ICUs (3 medical and 2 surgical ICUs) in 3 university hospitals and 1 universityaffiliated hospital for a mean duration of 8.6 months (range, 5-15 months). All consecutive patients who underwent mechanical ventilation for at least 7 days were eligible for neuromuscular evaluation. Patients were excluded if they had disease of the peripheral nervous system, bihemispheric or brainstem lesions, fewer than 2 limbs in which muscle strength could be tested, a language barrier expected to limit patient comprehension, or if they had been referred from another ICU.
After 7 days of mechanical ventilation, patients were screened daily for awakening and comprehension based on their responses to the following 5 orders: "Open (close) your eyes," "Look at me," "Open your mouth and put out your tongue," "Nod your head," and "Raise your eyebrows when I have counted up to 5." The first day that the patient responded to at least 3 of these orders on 2 consecutive evaluations at a 6-hour interval was considered day 1.
Identification of ICUAP Patients and Controls
On day 7, after persistent satisfactory awakening and comprehension were confirmed, muscle strength was evaluated using the Medical Research Council (MRC) score, a previously validated score that assesses 3 muscle groups in each of the upper and lower limbs. 10 Each muscle group score ranges from 0 (paralysis) to 5 (normal muscle strength), and the overall score from 0 to 60. In an attempt to reduce interexaminer variability, all of the investigators were trained by the same qualified neurologist (T.S.) in MRC score measurement. Because our goal was to identify patients with clinically significant weakness, patients with an MRC score less than 48 were a priori considered to have ICUAP, whereas those with an MRC score of 48 or higher, which indicates muscle strength of 5 (normal) or 4 (subnormal) in each limb segment, were considered controls.
Paraclinical Examinations in ICUAP Patients
To confirm the peripheral neuromuscular origin of the clinical weakness, all ICUAP patients underwent an electrophysiologic evaluation within 72 hours after day 7. To standardize the electrophysiologic procedure and interpretation, 2 trained electrophysiologists ( J.-P.L., F.M.) performed all electrophysiologic examinations using a portable electroneuromyogram machine (Keypoint portable, Medtronic France, Boulogne-Billancourt, France). All data were centrally analyzed according to standard laboratory references. 11 The ICUAP patients with persistent paresis at day 14 underwent muscle biopsy. The histologic samples were obtained from the left quadriceps or deltoid muscles with the patient under local anesthesia. Histologic analyses were performed in the Pathology Department of Henri-Mondor Hospital. Muscle samples were processed for hematoxylin-eosin, modified Gomori trichrome, and NADH-tetrazolium reductase and cytochrome C oxidase histoenzymatic reactions using standard procedures. Muscle fiber necrosis and regeneration, muscle fiber atrophy, and neurogenic changes were defined according to histologic criteria of Dubowitz et al. 12 The ICUAP patients underwent MRC score measurement weekly during the first month and monthly during a 9-month period until the regression of paresis (MRC score Ն48) or death.
The study protocol was approved by the Cochin Hospital Ethics Committee (Paris, France) provided the electrophysiologic examination was performed only in ICUAP patients, muscle biopsy was performed only in ICUAP patients with delayed clinical recovery, and peripheral nerve biopsy was not performed. Informed consent was obtained from ICUAP patients or relatives.
Data Collection
Clinical factors that may influence the onset of ICUAP were selected a priori and prospectively recorded between ICU admission and awakening (day 1) for both ICUAP patients and controls. These included potential risk factors at ICU admission, metabolic abnormalities, organ dysfunction-related variables (TABLE 1), and medications (TABLE 2). For medications suspected of influencing the onset of ICUAP, we recorded the number of patients who received the drug at least once before day 1 and the total number of days of administration and cumulative dosages in patients who received the drug.
Statistical Analysis
The ICUAP patients and controls were first compared using univariate analyses. Quantitative variables were reported as mean (SD), except when PARESIS IN THE ICU otherwise indicated, and were not dichotomized. Categorical variables were coded as 0 or 1. The t test and MannWhitney U test were used for comparison of quantitative variables; the 2 test and Fisher exact test were used for comparison of qualitative variables. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated separately for each variable using standard case-control methods with unconditional logistic regression models. 13 Variables, including drug exposure variables (number of patients receiving the drug, number of days of administration, and cumulative dosage) with PϽ.15 in univariate analysis, were then considered for multivariate analysis. First, a systematic search for statistical association between these variables was performed in the control patients, using correlation and regression analyses and 2 tests as appropriate. Second, statistically associated variables and variables with clinically suspected association were then analyzed in multiple 2ϫ2 analyses to assess firstorder interaction and confounding by fitting multiplicative models. Finally, variables identified from this selection were entered into a backward step-bystep logistic regression. PՅ.05 was considered statistically significant. All significance tests were 2-tailed. Data were analyzed using the BMDP software (University of California, Berkeley). 
RESULTS
During
Description of ICUAP Patients
The mean MRC score of the 24 ICUAP patients (extrapolated to 4 limbs when only 2 or 3 limbs could be tested) was 33.2 (11.5) (range, . The mean values of each item of the MRC score in the 24 ICUAP patients are presented in FIGURE 2. Proximal muscle strength was significantly less than distal muscle strength in both upper and lower limbs (PϽ.001). No difference was found between the right and left sides. In 2 patients, the electrophysiologic study was unreliable due to severe peripheral edema. In the other 22 patients, electrophysiologic examination revealed a sensorimotor axonal peripheral neuropathy, with a marked reduction in the amplitude of compound muscle action potentials and sensory nerve action potentials in the 4 limbs. Repetitive nerve stimulation did not reveal neuromuscular blockade. Abnormal spontaneous electromyographic activity was observed in 10 patients.
Among the 13 ICUAP patients who were still paralyzed at day 14, 2 were discharged to another hospital before muscle biopsy was performed, and muscle biopsy was not done in 1 patient. Of the 10 patients who underwent muscle biopsy, 4 had previously received both corticosteroids and neuromuscular blocking agents, 3 had received corticosteroids only, 2 had received neuromuscular blocking agents only, and 1 had not received either 
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drug. In all patients, histologic examination revealed primary myopathic changes (type 2 fiber atrophy with myosinolysis, n = 10; muscle fiber necrosis, n = 5) in addition to neurogenic muscle atrophy (n = 10). Only 1 patient had an inflammatory reaction and angiopathic signs.
Comparison of ICUAP and Control Patients
Univariate analysis of factors suspected to influence the occurrence of ICUAP is presented in Tables 1 and 2 . Among the baseline characteristics on admission, older age (P = .02), female sex (P=.01), and preexisting diabetes mellitus (P=.05) were significantly associated with ICUAP (Table 1) . A trend toward higher SAPS II and organ dysfunction and/or infection 15 score was also observed in ICUAP patients. Among the metabolic variables, the lowest serum sodium level observed between admission and day 1 and the highest blood urea nitrogen and blood glucose levels were significantly associated with ICUAP. Analysis of variables related to organ dysfunction showed that the number of days with dysfunction in at least 2 organs and the number of days of mechanical ventilation and of ICU stay before day 1 were significantly higher in ICUAP patients than control patients. Significantly more ICUAP patients also underwent extrarenal replacement therapy. A trend toward a higher frequency of septic shock was also observed. Twenty-six (27%) of the 95 patients received corticosteroids at least once before day 1 (septic shock, n = 9; chronic obstructive pulmonary disease [COPD] exacerbation, n=6; laryngeal dyspnea, n=6; organ transplantation, n = 2; systemic vasculitis, n = 1; non-Hodgkin lymphoma, n = 1; and unclear indication, n=1). All patients received supraphysiologic dosages. None of the patients received mineralocorticoids. Corticosteroids were administered significantly more frequently in ICUAP patients than in control patients (Table 2) . No relation between ICUAP and corticosteroid treatment duration or cumulative dosage was observed. Aminoglycosides and furosemide were also administered significantly more frequently to ICUAP patients, and a similar trend was observed for neuromuscular blockers.
There was no significant interaction among the 22 variables with PϽ.15 in univariate analysis. After 2ϫ 2 analyses, 11 variables were entered in the multivariate regression analysis: age, female sex, lowest serum sodium level, highest blood urea nitrogen and glucose levels, number of days with dysfunction in 2 or more organs, duration of mechanical ventilation before awakening, and administration (yes/ no) of corticosteroids, aminoglycosides, furosemide, and neuromuscular blockers. After regression analysis, female sex, number of days with dysfunction in 2 or more organs, duration of mechanical ventilation before awakening, and administration of corticosteroids remained independent risk factors of ICUAP ( The high number of patients excluded for preexisting neurologic disease is due to the recruitment of a large number of patients with peripheral neurologic disease on admission in 1 intensive care unit (ICU). 
Follow-up of the ICUAP Patients
The mean duration of paresis after awakening (day 1) in ICUAP survivors was 44.6 (79.2) days, with a median duration of 21 days (FIGURE 4) . No correlation was found between the initial MRC score and the duration of paresis. At the end of the 9-month follow-up period of the 24 ICUAP patients, 7 patients had died and 1 homeless patient had been lost to followup. Of the remaining 16 patients (67%), 12 returned home either at hospital discharge (n = 3) or after further treatment in a rehabilitation center (n=9), and 4 were in a long-term care facility or retirement home. All except 1 of these patients had recovered an MRC score of 48 or higher.
COMMENT
To our knowledge, this is the first prospective study of a multicenter, general ICU cohort of patients who had undergone mechanical ventilation and in whom a neuromuscular disorder was identified using a bedside clinical approach. Clinical evaluation of motor weakness in ICU patients is challenging. Two previous prospective cohort studies that included clinical diagnostic criteria were unable to shed light on this question, because a detailed description of the clinical abnormalities was not included in one 16 and the results were not applicable to a general ICU population in the other. 17 The most important factor that limits a reliable clinical evaluation is the alteration of consciousness, which may be due to various causes, including sepsis or administration of sedatives and analgesics. 18 Because of these difficulties, numerous investigators have previously identified ICU-acquired neuromuscular disorders by systematic electrophysiologic or histologic examination after a predefined duration of stay in the ICU, regardless of the level of consciousness. 4 However, the clinical relevance of this approach is questionable given that many ICU patients die without regaining consciousness (41% of the patients without previous neuromuscular disorders requiring Ն7 days of mechanical ventilation in our study). Furthermore, the high rate of electrophysiologic or histologic abnormalities, which has reached 100% in some studies, 7, 8, 19 raises questions about the discriminatory value of these tests in identifying patients with clinically significant neuromuscular disorders.
Our focus on the ICU patients who regained normal or almost normal consciousness has several advantages. First, awakening is a clinically important event during ICU stay, because this is usually the starting point of the process that will lead to weaning from the ventilator and to progressive recovery. Identification of a peripheral neuromuscular abnormality that might interfere with this recovery process is the cornerstone in patients who regain consciousness after septic, ischemic, or drugrelated encephalopathy. Second, return to normal or almost normal consciousness and comprehension allows all patients to undergo clinical assessment using simple bedside tests, such as limb muscle strength evaluation. This is especially important because electrophysiologic and histologic examinations are often difficult to perform in most ICUs and may be considered too invasive. 
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The systematic clinical detection of paresis in our study showed that a quarter of ICU patients who had undergone mechanical ventilation for 7 or more days and achieved satisfactory recovery of consciousness had severe motor weakness. This syndrome was characterized by a symmetrical alteration in muscle strength mainly in the proximal regions of the limbs. We found a sensory-motor axonopathy in all of the ICUAP patients. Furthermore, histologic features of primary myopathic change, along with neurogenic abnormalities, were also observed in all patients who still had paresis 1 week after the initial diagnosis. Although early studies 3 considered peripheral neuropathy to be the main mechanism of ICUAP, our findings suggest that both peripheral nerve and muscle are at the origin of ICUAP and that the term critical illness polyneuropathy may be too restrictive.
Neuromuscular dysfunction had resolved (MRC score, Ն48) within 3 weeks in half of our patients, and, among the 16 survivors at 9-month follow-up, 15 had recovered an MRC score of 48 or higher and 12 were able to return home. This finding indicates that improvement throughout several weeks or months is the rule for most patients. Although the recently summarized rehabilitation literature on longterm outcome of critical illness neuropathy or myopathy is predominantly based on retrospective case series, 20 our findings are consistent with the few prospective studies 6, 8, 21 that report follow-up of patients with critical illness polyneuropathy detected by electromyography.
In our study, 4 independent variables were associated with the occurrence of clinical motor weakness. The number of days with dysfunction in at least 2 organs before awakening was significantly higher in ICUAP patients than in the controls, suggesting that the duration, rather than the severity, of multiple-organ dysfunction plays a significant role in ICUAP. Thus, preventive or therapeutic interventions to reduce the risk of multiple-organ dysfunction may also decrease the risk of ICUAP.
We found a strong association between administration of corticosteroids and the occurrence of ICUAP. The deleterious effect of corticosteroids on neuromuscular function in ICU patients has been observed in several cohort studies of patients who received a combination of high doses of corticosteroids and neuromuscular blocking agents to treat severe acute asthma. 19, 22 The use of corticosteroids in the general ICU population would logically expose general ICU patients to similar neuromuscular complications. During our study period, one fourth of our patients received corticosteroids at least once, mostly for COPD exacerbation and septic shock. Our study is the first prospective cohort study, to our knowledge, to suggest a deleterious effect of corticosteroids in an unselected population of ICU patients. Non-ICU patients who receive corticosteroids are susceptible to developing histologic features of myopathy that include type 2 fiber atrophy and myosinolysis, which were commonly observed in our ICUAP patients. These lesions are the consequence of corticosteroid muscle receptor stimulation by exogenous corticosteroids 23 and are experimentally enhanced by muscle denervation. 24 Because all of our patients had axonal neuropathy, this may have contributed to the corticosteroid-specific muscle involvement. Interestingly, although corticosteroids were administered before day 1 more frequently in patients with ICUAP compared with those without ICUAP, no significant difference in the duration of administration or the cumulative dosage of corticosteroids was observed between the 2 groups. One explanation may be that the medical condition that prompts corticosteroid administration is indeed responsible for the neuromuscular dysfunction. However, neither COPD exacerbation nor septic shock was an independent predictor of ICUAP. Alternatively, corticosteroids may act as a trigger for neuromuscular dysfunction, which was previously unmasked or further maintained by other deleterious conditions, such as axonal neuropathy. Although we found a significant association between corticosteroids and ICUAP and not necessarily a definite causal relationship, this finding should prompt physicians to carefully weigh the indications of corticosteroids in critically ill patients and restrict their use to conditions such as septic shock, unresolved adult respiratory distress syndrome, and status asthmaticus in which corticosteroids have been shown to have a significant impact on morbidity and mortality. [25] [26] [27] [28] [29] The duration of mechanical ventilation before awakening was also significantly associated with the occurrence of ICUAP and likely reflects the negative effect of immobilization on neuromuscular function, given that increased expression of corticosteroid muscle receptors has been associated with complete immobilization. 30 Our finding raises the question of whether preservation of minimal muscle activity in ICU patients by minimal or interrupted sedation and analgesia or by regular and frequent passive physiotherapy may be beneficial.
Surprisingly, female sex was found to be independently associated with a higher rate of ICUAP in our study. There is no clear explanation for this finding. In our population, only 2 female patients were younger than 50 years. Muscle strength is physiologically lower in women than in men in both upper and lower limbs 31 and in postmenopausal women compared with premenopausal and postmenopausal women receiving hormone replacement therapy. 32 Pharmacokinetic differences between male and female patients might also contribute to this finding. 33 Although the use of aminoglycosides 21 and the presence of renal failure 9 have been previously associated with electrophysiologic or histologic abnormalities in ICU patients, they were not associated with ICUAP in our study. This may be due to a true lack of independent clinical effect or an insufficient sample size, even though our study was conducted in one of the largest cohorts of patients potentially at risk for ICUAP reported to date. Similarly, no significant difference was found between ICUAP and control patients with and without neuromuscular blockers. This finding does not rule out the possibility of a deleterious effect of specific modes of neuromuscular blocker administration, particularly continuous intravenous infusion. However, we could not compare this factor in our study, since few patients received continuous infusion of neuromuscular blockers (4 in the ICUAP and 2 in the control group). Such a comparison would require widespread use of neuromuscular blockers and a very large study, which may be difficult, given growing awareness of the potentially deleterious effect of neuromuscular blockers on the peripheral nervous system and the restricted conditions that justify their administration. 34 In our study, ICUAP patients had a significantly longer total duration of mechanical ventilation compared with control patients. The duration of mechanical ventilation after awakening and establishment of the diagnosis of ICUAP, which might be the most relevant assessment of the impact of ICUAP on the additional mechanical ventilation requirement, was also significantly longer in ICUAP patients than in controls. However, the exact contribution of neuromuscular disorders to delayed weaning from mechanical ventilation and prolonged ICU stay remains to be established through concomitant evaluations of peripheral and respiratory neuromuscular function and electrophysiology and inclusion of ICUAP in future analysis of variables influencing the duration of mechanical ventilation.
Although we studied ICU patients who recovered satisfactory awakening after at least 7 days of mechanical ventilation, ICUAP may also occur in patients who undergo mechanical ventilation for fewer than 7 days. Further research is warranted to determine the generalizability of our results to the overall ICU population of patients who undergo mechanical ventilation.
In summary, the use of simple bedside criteria allowed us to identify a high incidence of ICUAP among ICU patients during the recovery phase of severe critical illness. Patients with ICUAP have combined peripheral nerve and muscle involvement and require prolonged mechanical ventilation. The risk factors identified in our study suggest that preventive measures, including limiting corticosteroid administration to patients with evidence-based indications, may be warranted.
